HCL Technologies Ltd said it signed a deal with Australia-based independent clinical research organisation, Novotech for implementing Oracle's Siebel Clinical Trial Management System (CTMS) over the next few months. No financial details were provided.
The Siebel CTMS will support Novotech's complete spectrum of CTMS across Asia Pacific. Siebel CTMS will serve as a centralised repository to collect and track information about clinical trials. The system will allow management of clinical trials at different tiers-local, regional and global.
CTMS will also offer an aggregate view of clinical trails undertaken by Novotech and provide up to date information to Novotech's clients on project progress. It will also provide timely and accurate reports and dashboards to support tactical and strategic decision making, the company said.
HCL Technologies will work with Novotech in phases, starting by assessing the company's current proprietary CTMS. HCL will then implement and validate the Siebel CTMS and provide training to enable Novotech in using the Siebel CTMS successfully.
On Monday, HCL shares declined 1.8% to Rs406 on the Bombay Stock Exchange, while the benchmark Sensex closed 0.7% down at 20,852 points.
Drug firm Glenmark Pharmaceuticals Ltd said it successfully completed phase-III trials of Crofelemer, its anti-diarrheal drug used for HIV associated diarrhea.
The completion of the Phase-III trial was announced in the US by Glenmark's partners Napo Pharmaceuticals and Salix Pharmaceuticals, the company said in a filing to the Bombay Stock Exchange (BSE).
The trials are being conducted under a fast track status and have been a part of 'special protocol assessment' (SPA) agreement, it added.
"The results from these pivotal Phase-III studies for Crofelemer in the treatment of HIV associated diarrhea are very encouraging for Glenmark, as this will accelerate our goal to provide patients' access to this drug across multiple diarrheal conditions," Glenmark managing director and chief executive Glenn Saldanha said.
On Monday, Glenmark shares gained 3.6% to Rs376 on the Bombay Stock Exchange, while the benchmark Sensex closed 0.7% down at 20,852 points.
Retail asset finance provider, Magma Fincorp Ltd has tied up with Caterpillar India and its dealers Gmmco and TIPL. The tie up is for providing financial solutions to the customers of Caterpillar's entire range of construction and mining machines as a preferred financier in India.
Ashutosh Shukla, chief operating officer, Magma Fincorp said, "We are looking forward to a successful association with Caterpillar India and its dealers Gmmco and TIPL. The tie up will help our continuous effort to provide finance for a wider range of products to our customers and also help widen our customer base across the country."
Peter Tegg, managing director, Caterpillar Financial Services Asia, said "We are extremely excited about the tie up with Magma Fincorp as a preferred financier for our range of equipment. We believe this will help both companies to grow our respective businesses and help support the growth of India as a whole by providing more focus and enhanced service to the customer-base spread across the country."